Fig. 1From: Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective studyStudy design and schedule. Patients after minodronate (MIN) treatment for 2 years were asked for their willingness to switch to denosumab. Bone mineral density (BMD) and bone turnover markers (NTX and BAP) were evaluated as indicated. Adverse events were also recorded at baseline and all post visitsBack to article page